AI-assisted, human-published
09/16/2025 /Funding Events
AllRock Bio Inc. Raises $50M to Advance Innovative Therapy for Cardiopulmonary Diseases
AllRock Bio Inc. secures a $50 million Series A round of funding to advance ROC-101, a pan-ROCK inhibitor, through Phase 2 clinical development for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (ILD-PH).
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com